CrossAssetDataThe Company File
···
JAZZ

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Dublin. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $4.3 billion and a loss of $356 million (its filed statements).

Product business Pharmaceutical Preparations Dublin filings since 2003 9 of 9 filed
Ask the desk about JAZZ → Compare JAZZ with OGN → Price chart on TradingView ↗ Full EDGAR file ↗ Watch JAZZ →

Sector peers: OGNGMABELANZTS

6.2/10headline grade
vs its business-model standard
7.8/10past 6.4/10present 4.3/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.2 out of ten, 9 of 9 metrics filed: past 7.8 out of ten, present 6.4 out of ten, future 4.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 8.1 out of ten. +12.4% a year over 10 filed years; profitable in 7 of 10. 81st percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.8 out of ten. Share count shrank 0.8% a year. 18% of cash flow returned. Insiders: 59 sales, 0 purchases. 68th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.9 out of ten. ROE -8%: lost 8¢ per shareholder dollar. Leverage 63%: owes 63¢ per asset dollar. 69th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.0 out of ten. top 30% of 314 in its family; net margin -8.3%. 70th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.7 out of ten. bottom 47% of 315 in its family for leadership; chief executive since 2025. 47th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.1 out of ten. bottom 41% of 272 in its family for room to expand. 41st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.6 out of ten. top 44% of 307 in its family for growth drivers. 56th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 2.9 out of ten. bottom 29% of 234 in its family for expectations against reality. 29th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-03 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-03 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 2003. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Xywav 39%, Epidiolex Epidyolex 25%, Rylaze Enrylaze 9%, Zepzelca 7%, High Sodium AG Oxybate Product Royalty Revenue 5%, Defitelio Defibrotide 5%. By geography: United States 90%, Europe 8%, Other 2%. As tagged in its annual report (Form 10-K, filed 2026-02-24).

Who runs it

Gala, Renee D (President & CEO); Cozadd, Bruce C (Chairman & CEO); Johnson, Philip L (EVP & Chief Financial Officer); Patil, Neena M (EVP & Chief Legal Officer); Mulligan, Seamus (Chief Business Officer, International Business Development); Pearce, Samantha (EVP, Chief Commercial Officer); Carr, Patricia (SVP, Chief Accounting Officer); Henderson, Mary Elizabeth (SVP, Technical Operations); Iannone, Robert (EVP, Global Head of R&D & CMO); Cook, Jennifer E. (director); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-07.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.